A phase 1, 3 month, randomized, single-masked, sham-control, single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics activity of intravitreal LKA651 in patients with macular edema from diabetic macular edema, neovascular age-related macular degeneration, or retina vein occlusions.
